周五盘前交易中，BioNTech（BNTX）股价大涨7.25%，引发市场广泛关注。这一显著涨幅源于公司刚刚发布的一项重大研究突破。
据报道，BioNTech与映恩生物合作研发的一款实验性乳腺癌药物在临床试验中取得了成功。中期分析结果显示，这款新药在治疗乳腺癌方面的效果优于罗氏公司的老牌药物Kadcyla。使用这种新药的患者病情恶化或死亡的风险明显降低。该试验在中国进行，研究对象为228名癌症已扩散或不适合手术的患者，这些患者此前都接受过化疗和曲妥珠单抗治疗。
这一突破对BioNTech具有重要意义。作为公司与映恩生物合作开展的首个后期试验，也是BioNTech抗癌化合物首次在可能获得监管部门批准的研究中取得成功。癌症药物被视为BioNTech未来增长的基石，此次成功无疑增强了投资者对公司长期发展前景的信心。在新冠疫情期间因与辉瑞合作的疫苗项目而声名鹊起的BioNTech，正逐步展现其在癌症治疗领域的实力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.